Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group.
Treatment with bilateral orchidectomy was compared with Zoladex, 3.6 mg depot, plus flutamide, 250 mg t.i.d., in a randomized prospective study by the European Organization for Research and Treatment of Cancer (EORTC). Small but statistically significant differences in time to subjective and objective progression of disease were found in favor of Zoladex plus flutamide. However, time from objective progression to death was longer in the orchidectomy group. The clinical significance of these differences requires further follow-up and analysis. No difference was found in overall survival between the 2 treatment groups.
Denis
L
L
A.Z. Middelheim, Antwerp, Belgium.
Smith
P H
PH
De Moura
J L
JL
Newling
D W
DW
Bono
A
A
Keuppens
F
F
Robinson
M
M
Mahler
C
C
Sylvester
R
R
De Pauw
M
M
D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000175:diagnosis / Q000556:secondary; D002064:Buserelin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002277:Carcinoma / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D005485:Flutamide / Q000008:administration & dosage; D005500:Follow-Up Studies; D017273:Goserelin; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D009919:Orchiectomy; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate
D017273:Goserelin; D005485:Flutamide; D000410:Alanine Transaminase; D002064:Buserelin